BR0314631A - Derivados de pirrolidona como inibidores de maob - Google Patents

Derivados de pirrolidona como inibidores de maob

Info

Publication number
BR0314631A
BR0314631A BR0314631-6A BR0314631A BR0314631A BR 0314631 A BR0314631 A BR 0314631A BR 0314631 A BR0314631 A BR 0314631A BR 0314631 A BR0314631 A BR 0314631A
Authority
BR
Brazil
Prior art keywords
derivatives
maob inhibitors
pyrrolidone derivatives
disease
maob
Prior art date
Application number
BR0314631-6A
Other languages
English (en)
Inventor
Hans Iding
Synese Jolidon
Daniela Krummenacher
Rosa Maria Rodriguez-Sarmiento
Andrew William Thomas
Beat Wirz
Wolfgang Wostl
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0314631A publication Critical patent/BR0314631A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

"DERIVADOS DE PIRROLIDONA COMO INIBIDORES DE MAOB". A presente invenção refere-se a derivados de 4-pirrolidino racêmicos ou enantiomericamente puros, processos para sua preparação, composições farmacêuticas compreendendo os referidos derivados e seu uso na prevenção e tratamento de uma doença a qual é mediada por um inibidor de monoamina oxidase B, em particular mal de Alzheimer e demência senil.
BR0314631-6A 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de maob BR0314631A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02021319 2002-09-20
PCT/EP2003/010356 WO2004026825A1 (en) 2002-09-20 2003-09-18 Pyrrolidone derivatives as maob inhibitors

Publications (1)

Publication Number Publication Date
BR0314631A true BR0314631A (pt) 2005-08-02

Family

ID=32010924

Family Applications (4)

Application Number Title Priority Date Filing Date
BR0314299-0A BR0314299A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b
BRPI0314631-6A BRPI0314631B1 (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b, seu uso, e composição farmacêutica
BR0314631-6A BR0314631A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de maob
BR0314314-7A BR0314314A (pt) 2002-09-20 2003-09-18 Derivados do éter 4-pirrolidina-fenil-benzìlico

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR0314299-0A BR0314299A (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b
BRPI0314631-6A BRPI0314631B1 (pt) 2002-09-20 2003-09-18 Derivados de pirrolidona como inibidores de mao-b, seu uso, e composição farmacêutica

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0314314-7A BR0314314A (pt) 2002-09-20 2003-09-18 Derivados do éter 4-pirrolidina-fenil-benzìlico

Country Status (32)

Country Link
US (4) US7037935B2 (pt)
EP (3) EP1542971A1 (pt)
JP (3) JP4335141B2 (pt)
KR (3) KR100676015B1 (pt)
CN (3) CN100503562C (pt)
AR (3) AR041297A1 (pt)
AT (2) ATE459601T1 (pt)
AU (3) AU2003267381B2 (pt)
BR (4) BR0314299A (pt)
CA (3) CA2498785C (pt)
CY (1) CY1110745T1 (pt)
DE (2) DE60333202D1 (pt)
DK (1) DK1542970T3 (pt)
ES (2) ES2344557T3 (pt)
GT (3) GT200300204A (pt)
HK (3) HK1084383A1 (pt)
HR (3) HRP20050262A2 (pt)
JO (2) JO2604B1 (pt)
MX (3) MXPA05002880A (pt)
MY (3) MY134480A (pt)
NO (3) NO329754B1 (pt)
NZ (3) NZ538049A (pt)
PA (3) PA8583001A1 (pt)
PE (3) PE20050077A1 (pt)
PL (3) PL376018A1 (pt)
PT (1) PT1542970E (pt)
RU (3) RU2336268C2 (pt)
SI (1) SI1542970T1 (pt)
TW (3) TWI286132B (pt)
UY (3) UY27990A1 (pt)
WO (3) WO2004026827A1 (pt)
ZA (3) ZA200501137B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
GB0314373D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
KR100845366B1 (ko) * 2004-08-02 2008-07-09 에프. 호프만-라 로슈 아게 모노아민 산화효소 ｂ 억제제로서 벤질옥시 유도체
RU2378270C2 (ru) * 2004-08-02 2010-01-10 Ф. Хоффманн-Ля Рош Аг Бензилокси-производные в качестве ингибиторов моноаминоксидазы b
RU2007129642A (ru) 2005-02-25 2009-03-27 Ф.Хоффманн-Ля Рош Аг (Ch) Таблетки с улучшенным распределением лекарственного вещества
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
AU2006224878B2 (en) * 2005-03-15 2011-02-17 F. Hoffman-La Roche Ag Method for preparing enantiomerically pure 4-pyrrolidinophenyl benzyl ether derivatives
ATE472529T1 (de) * 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
TW200728258A (en) * 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) * 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
EP2171478A4 (en) * 2007-03-30 2013-01-30 Univ California IN VIVO IMAGING METHOD FOR SULPHOTRANSFERASES
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
CZ304053B6 (cs) * 2011-08-22 2013-09-04 Farmak, A. S. Zpusob prípravy 2-[4-[(methylamino)karbonyl]-1-H-pyrazol-1-yl]adenosinu monohydrátu
KR102018284B1 (ko) * 2013-02-28 2019-09-05 삼성디스플레이 주식회사 박막 트랜지스터 어레이 기판 및 이를 포함하는 유기 발광 표시 장치
KR20150127172A (ko) 2013-03-14 2015-11-16 다트 뉴로사이언스 (케이만) 엘티디. Mao 억제제로서 치환된 나프티리딘 및 퀴놀린 화합물
CZ305213B6 (cs) 2013-04-29 2015-06-10 Farmak, A. S. Polymorf E 2-[4-[(methylamino)karbonyl]-1H-pyrazol-1-yl]adenosinu a způsob jeho přípravy
MX361764B (es) * 2013-10-29 2018-12-17 Hoffmann La Roche Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.
US10421716B2 (en) 2014-12-23 2019-09-24 Convergence Pharmaceuticals Limited Process for preparing alpha-carboxamide pyrrolidine derivatives
EP3273946A1 (en) * 2015-03-27 2018-01-31 F. Hoffmann-La Roche AG Pharmaceutical formulation comprising sembragiline
EP3689870B1 (en) 2017-09-27 2022-07-13 Kagoshima University Analgesic drug using pac1 receptor antagonistic drug
MX2020003811A (es) 2017-10-05 2021-01-15 Biogen Inc Proceso para preparar derivados de alfa-carboxamida pirrolidina.
CN108299272B (zh) * 2018-01-31 2019-10-18 福州大学 一种合成1-氯-2,2,2-三氟亚乙基取代咯酮化合物的方法
EP3762364B1 (en) 2018-03-08 2023-08-23 Sunshine Lake Pharma Co., Ltd. Pyrrolidineamide derivatives and uses thereof
US20220184081A1 (en) 2019-02-27 2022-06-16 Kagoshima University Antipruritic agent using pac1 receptor antagonist
WO2021225161A1 (ja) 2020-05-08 2021-11-11 国立大学法人鹿児島大学 Ｐａｃ１受容体拮抗薬を用いた抗うつ・抗不安薬
CN112851561A (zh) * 2021-01-29 2021-05-28 南京艾美斐生物医药科技有限公司 一种nr6a1蛋白受体抑制剂及其制备和应用
WO2022268520A1 (de) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Verwendung von substituierten pyrrolidinonen oder deren salzen zur steigerung der stresstoleranz in pflanzen.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348393A (en) * 1978-06-09 1982-09-07 Delalande S.A. N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones
FR2500831A1 (fr) 1981-02-27 1982-09-03 Delalande Sa Nouvelles n-aryl-oxazolidinones et -pyrrolidinones
JP2657324B2 (ja) 1989-04-19 1997-09-24 大塚製薬株式会社 ヘテロ環を有するフェニルカルボン酸誘導体
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
JP3258027B2 (ja) 1996-03-15 2002-02-18 サマーセット・ファーマシューティカルズ・インコーポレイテッド セレジリン投与による末梢ニューロパシーの予防および治療方法
US5683404A (en) * 1996-06-05 1997-11-04 Metagen, Llc Clamp and method for its use
DE19841895A1 (de) 1998-09-11 2000-03-23 Degussa Neues Verfahren zur Herstellung von 3-Amino-2-oxo-pyrrolidinen, neue Zwischenprodukte und deren Verwendung
EP1165546A2 (en) * 1999-04-02 2002-01-02 Du Pont Pharmaceuticals Company Novel lactam inhibitors of matrix metalloproteinases, tnf-alpha, and aggrecanase
AU1359801A (en) 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
DE60113965T2 (de) * 2000-02-10 2006-07-06 Potencia Medical Ag Behandlung der harninkontinenz mit kabelloser energiezufuhr
US7442165B2 (en) * 2000-02-14 2008-10-28 Obtech Medical Ag Penile prosthesis
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter
US20040267291A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with non-mechanical attachment mechanism
US20040267292A1 (en) * 2003-06-27 2004-12-30 Byrum Randal T. Implantable band with transverse attachment mechanism

Also Published As

Publication number Publication date
BR0314314A (pt) 2005-07-26
AU2003270213B8 (en) 2009-03-05
KR100676015B1 (ko) 2007-01-30
US20060122235A1 (en) 2006-06-08
MXPA05002881A (es) 2005-05-27
PL216030B1 (pl) 2014-02-28
AR041299A1 (es) 2005-05-11
MXPA05002878A (es) 2005-05-27
HRP20050261A2 (en) 2006-05-31
US20040106650A1 (en) 2004-06-03
WO2004026826A1 (en) 2004-04-01
WO2004026825A1 (en) 2004-04-01
TW200408624A (en) 2004-06-01
KR20050057456A (ko) 2005-06-16
ES2338646T3 (es) 2010-05-11
ATE459601T1 (de) 2010-03-15
RU2336268C2 (ru) 2008-10-20
MY133332A (en) 2007-11-30
CA2498785A1 (en) 2004-04-01
ZA200501137B (en) 2006-12-27
DE60331559D1 (de) 2010-04-15
GT200300205A (es) 2004-04-29
JP2006510596A (ja) 2006-03-30
WO2004026827A1 (en) 2004-04-01
US7151111B2 (en) 2006-12-19
AR041297A1 (es) 2005-05-11
GT200300204A (es) 2004-04-29
JP4335141B2 (ja) 2009-09-30
CA2496756C (en) 2012-01-10
BR0314299A (pt) 2005-12-13
CA2496756A1 (en) 2004-04-01
AU2003270213A1 (en) 2004-04-08
PA8583601A1 (es) 2004-09-16
HRP20050263A2 (en) 2006-12-31
HRP20050263B1 (hr) 2013-09-30
NO20050652L (no) 2005-03-08
TW200413350A (en) 2004-08-01
AU2003267381B2 (en) 2009-08-27
KR20050057450A (ko) 2005-06-16
PA8583501A1 (es) 2004-04-23
ATE472530T1 (de) 2010-07-15
CN1681777A (zh) 2005-10-12
PE20050078A1 (es) 2005-02-28
US20040097578A1 (en) 2004-05-20
KR100681586B1 (ko) 2007-02-09
AU2003273901A1 (en) 2004-04-08
CN100400509C (zh) 2008-07-09
RU2323209C2 (ru) 2008-04-27
DK1542970T3 (da) 2010-08-02
GT200300206A (es) 2004-04-29
PL376019A1 (en) 2005-12-12
UY27990A1 (es) 2004-03-31
RU2005111968A (ru) 2006-11-10
JP2006503833A (ja) 2006-02-02
EP1542969B1 (en) 2010-03-03
EP1542970A1 (en) 2005-06-22
BRPI0314631B1 (pt) 2018-04-17
PL376021A1 (en) 2005-12-12
MXPA05002880A (es) 2005-05-27
PA8583001A1 (es) 2004-04-23
PE20050077A1 (es) 2005-03-01
EP1542969A1 (en) 2005-06-22
KR100676014B1 (ko) 2007-01-30
NO20050701L (no) 2005-03-02
CN1681778A (zh) 2005-10-12
US7122562B2 (en) 2006-10-17
JP2006503834A (ja) 2006-02-02
RU2336267C2 (ru) 2008-10-20
TWI331994B (en) 2010-10-21
CN100383118C (zh) 2008-04-23
ZA200501311B (en) 2006-10-25
RU2005111974A (ru) 2006-01-20
UY27993A1 (es) 2004-03-31
HK1083499A1 (en) 2006-07-07
CN100503562C (zh) 2009-06-24
AU2003267381A1 (en) 2004-04-08
JO2605B1 (en) 2011-11-01
JP4335140B2 (ja) 2009-09-30
SI1542970T1 (sl) 2010-08-31
ES2344557T3 (es) 2010-08-31
JP4335142B2 (ja) 2009-09-30
NZ538048A (en) 2007-05-31
AU2003273901B2 (en) 2008-07-10
US20040116707A1 (en) 2004-06-17
NZ538046A (en) 2007-08-31
RU2005111969A (ru) 2006-01-20
DE60333202D1 (de) 2010-08-12
JO2604B1 (en) 2011-11-01
HK1084383A1 (en) 2006-07-28
EP1542971A1 (en) 2005-06-22
CA2498785C (en) 2011-07-26
NO20050665L (no) 2005-04-18
MY135696A (en) 2008-06-30
PL376018A1 (en) 2005-12-12
MY134480A (en) 2007-12-31
PE20050079A1 (es) 2005-03-01
US7235581B2 (en) 2007-06-26
HRP20050262A2 (en) 2006-06-30
AU2003270213B2 (en) 2009-02-12
ZA200501557B (en) 2005-09-08
EP1542970B1 (en) 2010-06-30
CA2498335A1 (en) 2004-04-01
NZ538049A (en) 2007-05-31
KR20050057466A (ko) 2005-06-16
NO329754B1 (no) 2010-12-13
AR041298A1 (es) 2005-05-11
CN1681779A (zh) 2005-10-12
PT1542970E (pt) 2010-07-19
TWI337604B (en) 2011-02-21
HK1083498A1 (en) 2006-07-07
NO330012B1 (no) 2011-02-07
US7037935B2 (en) 2006-05-02
TW200410935A (en) 2004-07-01
TWI286132B (en) 2007-09-01
CY1110745T1 (el) 2015-06-10
UY27991A1 (es) 2004-03-31

Similar Documents

Publication Publication Date Title
BR0314631A (pt) Derivados de pirrolidona como inibidores de maob
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DK1789398T3 (da) 2-amino-quinazolin derivater anvendelige som inhibitorer af B-sekretase (BACE)
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
MA29403B1 (fr) Forme cristalline d'un compose quinolinone-carboxamide
SG151336A1 (en) 1,3,4-oxadiazol-2-ones as ppar delta
BRPI0416287A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por inibidores de accß e sua utilização
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
BRPI0510451A (pt) compostos, processo para a manufatura dos mesmos, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas de ppar(delta) e/ou de ppar(alfa) e sua utilização
BR9909870A (pt) Pirrolidinas como inibidores de neuraminidases
BR0317714A (pt) Oxazóis como realçadores de mglur1
BR0313543A (pt) 2,3-diidro-isoindol-1-onas com atividade de inibição de mao-b
BR0313922A (pt) Compostos de piperidina de benzoìla
EP1597234A4 (en) NEW COMPOUNDS
BRPI0512404A (pt) inibidores de mao-b
DE602004021114D1 (de) Verwendung von cyclischen bioisosteren von purin-system-derivaten zur behandlung von erkrankungen durch störungen der nitrergen und dopaminergen systeme
EA200500957A1 (ru) Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний
DE602004008960D1 (de) Verwendung von 1-thiadibenzo e,h azulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems
DE10390702D2 (de) 2-Methylthiazolidin-2,4-Dicarbonsäure und deren Salze zur Behandlung von neurodegenerativen Erkrankungen
HN2002000113A (es) Sales tartrato de 5, 8, 14 - triazatetraciclo [10.3.1.02,11.04,9] hexadeca - 2 (11), 3,5,7,9 - pentaeno y composiciones farmaceuticas de las mismas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. C07D 207/26, 401/04; A61P 25/00

Ipc: C07D 207/26 (2011.01), C07D 401/04 (2011.01), A61P

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.